Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.7%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (92.2% of net sales) and other (7.8%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (74.5%), Europe (16%) and other (9.5%).

Number of employees : 13 600 people.
Sales per Business
20192020Delta
Innovative Medicines22 449.00100.6%24 689.00100.2% +9.98%
USD in Million
Sales per region
20192020Delta
United States16 645.0074.6%18 217.0073.9% +9.44%
Europe3 811.0017.1%4 135.0016.8% +8.5%
Other International1 993.008.9%2 337.009.5% +17.26%
USD in Million
Managers
Name Title Age Since
Daniel O'Day Chairman & Chief Executive Officer 56 2019
Andrew Dickinson Chief Financial Officer 51 2019
Merdad Parsey Chief Medical Officer 58 2019
Flavius Martin Executive Vice President-Research - 2021
Brett Pletcher Secretary, Chief Compliance Officer & Executive VP 53 -
Kevin E. Lofton Lead Independent Director 66 2020
Kelly A. Kramer Independent Director 53 2016
Jacqueline K. Barton, Dr. Independent Director 68 2018
Harish M. Manwani Independent Director 67 2018
Sandra J. Horning, Dr. Independent Director 72 2020
Members of the board
Name Title Age Since
Daniel O'Day Chairman & Chief Executive Officer 56 2019
Kevin E. Lofton Lead Independent Director 66 2020
Kelly A. Kramer Independent Director 53 2016
Jacqueline K. Barton, Dr. Independent Director 68 2018
Harish M. Manwani Independent Director 67 2018
Sandra J. Horning, Dr. Independent Director 72 2020
Javier Rodriguez Independent Director 50 2020
Anthony Welters Independent Director 66 2020
Jeffrey A. Bluestone, Dr. Independent Director 67 2020
Shareholders
NameEquities%
Capital Research & Management Co. (Global Investors) 114,548,108 9.13%
The Vanguard Group, Inc. 99,889,850 7.96%
Capital Research & Management Co. 64,780,000 5.16%
SSgA Funds Management, Inc. 55,182,125 4.40%
Capital Research & Management Co. (International Investors) 39,450,160 3.14%
Dodge & Cox 37,266,692 2.97%
Capital Research & Management Co. (World Investors) 36,976,309 2.95%
BlackRock Fund Advisors 29,107,416 2.32%
Geode Capital Management LLC 22,298,484 1.78%
Northern Trust Investments, Inc.(Investment Management) 14,477,966 1.15%
Holdings
NameEquities%Valuation
GALAPAGOS NV (GLPG) 16,707,477 25.5% 935,167,276 USD
ARCUS BIOSCIENCES, INC. (RCUS) 13,913,029 19.8% 563,060,284 USD
ALLOGENE THERAPEUTICS, INC. (ALLO) 7,486,689 5.25% 111,701,400 USD
TANGO THERAPEUTICS, INC. (TNGX) 4,852,550 5.54% 53,086,897 USD
JOUNCE THERAPEUTICS, INC. (JNCE) 5,539,727 10.8% 46,256,720 USD
AGENUS INC. (AGEN) 11,111,111 4.33% 35,777,777 USD
SIERRA ONCOLOGY, INC. (SRRA) 725,283 4.82% 15,767,652 USD
HOOKIPA PHARMA INC. (HOOK) 2,092,799 8.01% 4,876,222 USD
Markets and indexes
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 100, S&P 500, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  GILD:US
- Reuters Code :  GILD.O
- Datastream Code :  @GILD
Company contact information
Gilead Sciences, Inc.
333 Lakeside Drive
CA 94404 San Mateo, California

Phone : +1 650 574 3000
Fax : +1 650 578 9264
web site : http://www.gilead.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Gilead Sciences, Inc.